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LETTER TO THE EDITOR
Reply to the letter from Dr Meenan
Sir - In reply to the above, rather than trying to 'lay blame
at the door of an anti-folate effect' for the observed cocar-
cinogenic effect of sulphasalazine in the rat dimethylhy-
drazine (DMH) model for colonic cancer as Dr Meenan
suggests, we stated that this hypothesis needed further in-
vestigation. We subsequently did this. The aim of the experi-
ment was to elucidate whether a low serum folate level
contributed to the development of DMH induced colonic
cancer in the rat with or without the addition of sulphasa-
lazine.
Forty-eight male wistar rats received 240 milligrams (mg)
total DMH per kilogram body weight in weekly subcutan-
eous injections over 20 weeks. Twenty-four rats received no
folic acid; the remainder had 6 mg folic acid per kilogram
added to a synthetic diet. Twelve rats per group also had
60 mg per kilogram per day of sulphasalazine in their diet.
Serum folate levels were determined by radioimmunoassay
(Simultrac, Becton Dickenson). The following results were
obtained:
In this experiment, rats receiving sulphasalazine but no
folic acid had no tumours. These results do not support the
hypothesis that low serum folate levels contribute to the
development of colonic cancer. It is of interest that under the
conditions of this experiment sulphasalazine was not co-
carcinogenic even in the presence of folate depletion.
However, the variables in this experiment compared to the
first experiment include a lower dose of DMH and, more
importantly, a synthetic diet rather than a pellet diet. From
previous experiments in our laboratory the synthetic diet
used is associated with a reduction in the production of
neoplasia in this animal model.
Consequently, we agree with Dr Meenan that to 'lay blame
at the door of the anti-folate effect' for the co-carcinogenic
effect of salazopyrin is indeed unjustified.
Alan E. Davis and Frankie Patterson
Gastrointestinal Unit,
The Prince of Wales Hospital,
High Street,
Randwick NSW 2031,
Australia.
Table I Comparison of incidence of tumours among rats in
different study groups
Folic No. of rats % of rats
Sulphasalazinea acid n with tumours with tumours
- + 12 10 83
- - 12 6 50
+ + 12 3 25
+ - 12 0 0
= not added to diet: + = added to diet). aSignificant difference
between rats on sulphasalazine and rats not on sulphasalazine
(± folate). Corrected Chi-squared, df = 1, P <0.05.
Table II Comparison of the mean number of tumours per rat in each study group with
fasting serum folate levels
Folic Mean tumours Fasting serum Folic acid
Sulphasalazine acid per rat ± s.e. folic acid ngml-' range ngml-'
- + 1.1 0.2 56.2 20.6-104.0
- - 0.7 0.2 6.8 3.6- 10.5
+ + 0.7 0.4 69.5 32.6-105.2
+ - *0.0 0.0 3.6 1.9- 6.3
(-= not added to diet: + = added to diet). *Student's t-test; compared with all
groups P> 0.02. NB. Rats with no tumours were not excluded from this analysis.
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